Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) Equity Ratio (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Equity Ratio for 6 consecutive years, with 0.54 as the latest value for Q4 2025.

  • Quarterly Equity Ratio fell 17.12% to 0.54 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.54 through Dec 2025, down 17.12% year-over-year, with the annual reading at 0.54 for FY2025, 17.12% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.54 at TScan Therapeutics, down from 0.55 in the prior quarter.
  • The five-year high for Equity Ratio was 0.87 in Q1 2022, with the low at 0.46 in Q2 2021.
  • Average Equity Ratio over 5 years is 0.59, with a median of 0.6 recorded in 2023.
  • The sharpest move saw Equity Ratio skyrocketed 287.07% in 2022, then plummeted 48.11% in 2023.
  • Over 5 years, Equity Ratio stood at 0.85 in 2021, then plummeted by 41.57% to 0.5 in 2022, then grew by 11.0% to 0.55 in 2023, then increased by 17.13% to 0.65 in 2024, then decreased by 17.12% to 0.54 in 2025.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.54, 0.55, and 0.59 for Q4 2025, Q3 2025, and Q2 2025 respectively.